Table 2.
Demographic and clinical characterization among different profiles.
| Parameter | Non-survivors (n = 5) | Survivors 1 (n = 15) | Survivors 2 (n = 10) | Qui-Square | |
|---|---|---|---|---|---|
| Cramer's V | p-value | ||||
| Gender, n (%) | |||||
| Female | 1 (20) | 4 (27) | 7 (70) | 0.392 | 0.099 |
| Male | 4 (80) | 11 (73) | 3 (30) | ||
| Underlying diseases, n (%) | |||||
| Autoimmune Disease | – | – | 1 (9) | – | – |
| Active Neoplasia | 1 (20) | 3 (20) | 1 (9) | 0.126 | 0.787 |
| Asthma | – | 1 (7) | – | – | – |
| Chronic Kidney Disease | – | 3 (20) | 2 (18) | 0.200 | 0.549 |
| COPD | 1 (20) | 1 (7) | 2 (18) | 0.248 | 0.396 |
| Diabetes Mellitus | 2 (40) | 4 (27) | 3 (27) | 0.200 | 0.549 |
| Hypertension | 3 (60) | 9 (60) | 7 (70) | 0.098 | 0.866 |
| Treatment, n (%) | |||||
| No Treatment | 0 | 3 (20) | 2 (20) | 0.200 | 0.549 |
| Corticosteroids | 3 (60) | 2 (13) | 2 (20) | 0.394 | 0.097 |
| Hydroxychloroquine | 1 (20) | 0 | 4 (40) | 0.482 | 0.031 |
| Hydroxychloroquine+Azithromycin | 2 (40) | 13 (87) | 2 (13) | 0.629 | 0.003 |
COPD, Chronic Obstructive Pulmonary Disease.